Xenon Pharmaceuticals Inc. has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the offering, but it is valued up to $51.75 million. The company plans to list on the Nasdaq Global Market under the symbol XENE. Underwriters for the offering were initially listed as Jefferies and Wells Fargo.

Xenon is a clinical-stage biopharmaceutical company that discovers and develops differentiated therapeutics for orphan indications. The core enabling discovery platform is focused on studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. The Extreme Genetics discovery platform yielded the first approved gene therapy product in the European Union.

ALSO READ: Top Analyst Upgrades and Downgrades: Altria, BofA, FireEye, Ford, J.P. Morgan, Linn Energy and More

Pharmaceutical partners include Teva Genentech and Merck (through its affiliate, Essex Chemie). These collaborations have aggregately generated more than $140 million in non-equity funding to date, with the potential to provide more than $1.0 billion in future milestone payments, as well as royalties and co-promotion income on product sales.

The company’s most advanced product candidate is TV-45070 (formerly XEN402). Teva is currently conducting a 300-patient, randomized Phase 2b clinical trial of TV-45070 in osteoarthritis of the knee. The company is currently planning additional development of TV-45070 in neuropathic pain indications.

At the end of June 2014, Xenon has cash, cash equivalents and marketable securities of $44.7 million, which excludes an $8 million milestone payment it received in August 2014 from Genentech. Over the next 24 months, Xenon looks to potentially gain $40.5 million in milestone payments, including the $8 million from Genentech.

ALSO READ: The Best Economies in the World

The company had its last equity financing in 2006.

Xenon has plans for use of the proceeds from this offering but has not listed definite amounts. It plans on devoting money to the preclinical and early development of its Dravet Syndrome and XEN801 programs and to further fund the genetic research and drug discovery activities using its Extreme Genetics Platform.

Related Articles

• 9 Analyst Stocks to Buy Under $10 With Massive Upside Potential

• What the Apple Watch Was Supposed to Have, but Didn't

• RBC's 4 Gold Stocks to Buy With Potential Upside of 40% or More